Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study
Riccardo Campi, Alessio Pecoraro, Eduard Roussel, Daniele Amparore, Andrea Mari, Francesco Montorsi, Francesco Porpiglia, Maarten Albersen, Umberto Capitanio, Andrea Minervini, Sergio Serni, Riccardo Bertolo
Topics & Concepts
MedicinePembrolizumabRenal cell carcinomaClear cell renal cell carcinomaCohortInternal medicineKidney cancerOncologyDiseaseCohort studySurgeryCancerImmunotherapyRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers